Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Sees Large Growth in Short Interest

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 4,240,000 shares, a growth of 18.1% from the June 30th total of 3,590,000 shares. Currently, 11.7% of the company’s shares are short sold. Based on an average daily trading volume, of 338,400 shares, the short-interest ratio is presently 12.5 days.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 7,351 shares of the stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the sale, the insider now owns 232,681 shares in the company, valued at $3,024,853. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Y-mAbs Therapeutics news, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the transaction, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas Gad sold 7,351 shares of the stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 99,444 shares of company stock worth $1,203,925. Company insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its stake in shares of Y-mAbs Therapeutics by 17.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock worth $2,432,000 after buying an additional 52,610 shares during the period. Bank of New York Mellon Corp raised its position in Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after acquiring an additional 8,974 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Y-mAbs Therapeutics during the fourth quarter valued at $562,000. Federated Hermes Inc. lifted its holdings in Y-mAbs Therapeutics by 4,708.0% during the fourth quarter. Federated Hermes Inc. now owns 44,474 shares of the company’s stock valued at $303,000 after purchasing an additional 43,549 shares in the last quarter. Finally, Sapient Capital LLC acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at about $298,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 3.0 %

Y-mAbs Therapeutics stock opened at $12.15 on Tuesday. The firm has a market cap of $533.18 million, a PE ratio of -24.80 and a beta of 0.66. The stock’s 50 day simple moving average is $12.09 and its two-hundred day simple moving average is $13.62. Y-mAbs Therapeutics has a 12 month low of $4.60 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $19.93 million for the quarter, compared to analyst estimates of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. On average, equities research analysts forecast that Y-mAbs Therapeutics will post -0.52 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on YMAB shares. Truist Financial started coverage on Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 price target for the company. HC Wainwright upped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $17.86.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.